< Back to the team

L. Chalus

Lead Technical Operations

Pharmaceutical industry (R&D expert) & expertise in GMP Manufactruing .

Lionel Chalus (Ingineer) brings 25 years of experience in the pharma industry with roles at Shering-Plough, Genopoïetic, Valneva, Bio-Elpida mainly in Research and pharmaceutical development and aquired a strong expertise in GLP/GMP manufacturing.

Lionel has participated in the development of several drug candidates, particularly in cell therapies in the field of oncology and tissue regeneration.

Linkedin-in
Evolution of British Sports Betting: Betzoid's Industry Analysis

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page